( SCHLIEREN (Zurich) Switzerland March...)Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients,Health

SCHLIEREN (Zurich), Switzerland, March 13, 2007 - Cytos Biotechnology AG (SWX:CYTN) reported today positive results from a phase IIa study with CYT003-QbG10, an immunotherapeutic product candidate for the treatment of allergic diseases. The study included 40 patients suffering from mild to moderate allergic rhinitis due to grass pollen allergy (hay fever). The trial investigated in a doubleblind setting the safety, tolerability and exploratory efficacy of two different formulations of CYT003-QbG10 monotherapy to placebo, and in an open-label setting a CYT003-QbG10 formulation comprising a low dose of grass pollen extract. Exploratory efficacy of CYT003-QbG10 was determined by assessing the allergic disease status of the patients before and after treatment by the conjunctival provocation test, yielding a symptom score ranging from 0 to 15 points.

All formulations of CYT003-QbG10 tested were safe and well tolerated. Treatment with CYT003-QbG10 monotherapy led to a significant (p<0.05) improvement of allergy symptoms in the conjunctival provocation test when compared to placebo. A reduction of the median symptom score from 9 points pre-treatment to 5 points post-treatment was achieved (for placebo: 9 points pre-treatment to 8 points post-treatment). For the formulation of CYT003-QbG10 plus grass pollen extract, the median symptom score was reduced from 9 points pre-treatment to 4 points post-treatment, whereas for the formulation of CYT003-QbG10 plus alum, no significant reduction was observed when compared to placebo.

Dr. Wolfgang Renner, CEO of Cytos Biotechnology, commented: "These results mark a further important milestone in the development of CYT003-QbG10 monotherapy and confirm prior open-label observations of efficacy of this product in a double-blind, placebo-controlled setting. At this stage, we are assessing various parameters of this promising Immunodrug™ candidate such as different formulations,
'"/>